ITLN1, conversely, antagonizes tumor neovascularization and MDSC accumulation via IL-17D/CXCL2 axis modulation, thereby reshaping the immunosuppressive TME—a mechanism aligning with its prognostic significance in both CRC and ovarian cancer (56, 57). The gene discussed is IL17D; the disease is ovarian cancer.